Benzinga · Feb 10, 2026
Hainan Helpson Medical & Biotechnology Strikes Deal With Xiaoyun Chen To Acquire Invention Patent Of An Topiroxostat Nanoemulsion And Method for Its Preparation For $8.82M
SEC.
CP
AMEX · CPHI
China Pharma Holdings, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$0.59
Down-$0.02 (-3.56%)
Updated Nov 5, 2026, 9:34 AM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 4.77M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- $0.38 – $19.19
- Volume
- 34.6K
- Avg. volume
- 16.42K
Price performance · CPHI
CPHI price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
CPHI closed at $0.59 after 21 trading sessions, down 30.88% for the selected period.
- Last close
- $0.59
- Period change
- -30.88%
- Period low
- $0.59
- Period high
- $0.96
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $0.63 | $0.643 | $0.5826 | $0.5875 | 34.6K |
| Nov 3, 2026 | $0.6184 | $0.6354 | $0.584 | $0.6092 | 71.78K |
| Nov 2, 2026 | $0.6195 | $0.6354 | $0.5982 | $0.6063 | 105.41K |
| Oct 30, 2026 | $0.65 | $0.6748 | $0.6065 | $0.6249 | 184.29K |
| Oct 29, 2026 | $0.6292 | $0.6798 | $0.61 | $0.65 | 154.58K |
| Oct 28, 2026 | $0.6095 | $0.6595 | $0.601 | $0.62 | 613.6K |
| Oct 27, 2026 | $0.6599 | $0.6599 | $0.6101 | $0.63 | 72.83K |
| Oct 26, 2026 | $0.65 | $0.65 | $0.621 | $0.6348 | 55.07K |
| Oct 23, 2026 | $0.6675 | $0.6767 | $0.6306 | $0.6586 | 190.16K |
| Oct 22, 2026 | $0.6862 | $0.6995 | $0.6647 | $0.6767 | 125.36K |
| Oct 21, 2026 | $0.7068 | $0.73 | $0.685 | $0.697 | 128.82K |
| Oct 20, 2026 | $0.693 | $0.74 | $0.6711 | $0.7244 | 154.34K |
| Oct 19, 2026 | $0.6886 | $0.7298 | $0.6611 | $0.6851 | 131.17K |
| Oct 16, 2026 | $0.7201 | $0.7373 | $0.6743 | $0.7099 | 306.49K |
| Oct 15, 2026 | $0.7162 | $0.74 | $0.6721 | $0.7279 | 331.94K |
| Oct 14, 2026 | $0.72 | $0.7219 | $0.6701 | $0.72 | 306.62K |
| Oct 13, 2026 | $0.8409 | $0.869 | $0.693 | $0.7514 | 585.96K |
| Oct 12, 2026 | $0.8044 | $0.869 | $0.7431 | $0.869 | 967.27K |
| Oct 9, 2026 | $0.923 | $1.0901 | $0.80 | $0.8705 | 2.29M |
| Oct 8, 2026 | $0.768 | $1.19 | $0.7401 | $0.96 | 20.04M |
| Oct 7, 2026 | $0.68 | $1.28 | $0.643 | $0.85 | 67.51M |
Latest CPHI news
The latest Smart Investors Daily articles mentioning CPHI.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CPHI research
Overview
Company profile and research snapshot.
Company profile
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
defenseworld.net · Dec 12, 2025
China Pharma (NYSE:CPHI) Stock Price Down 10.2% – Should You Sell?
Shares of China Pharma Holdings, Inc. (NYSE: CPHI - Get Free Report) were down 10.2% during mid-day trading on Thursday. The stock traded as low as $1.48 and last traded at $1.50. Approximately 42,122 shares changed hands during mid-day trading, a decline of 48% from the average daily volume of 81,489 shares. The stock had
prnewswire.com · Nov 4, 2025
From Pandemic Innovation to Global Collaboration: Taiwan's TCM Shines at CPHI Frankfurt 2025
/PRNewswire/ -- The Taiwan Traditional Chinese Medicine (TCM) Pavilion, guided by the Department of Chinese Medicine and Pharmacy (DCMP) under the Ministry of
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
